Clinical trial
MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors
NCT00003028 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00003028 |
|---|---|
| Title | MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors |
| Official title | Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every 3 Weeks |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | sabarubicin |
| Enrollment | 5 |
| Start date | Apr 1, 1997 |
| First posted | Jun 16, 2004 |
| Last update posted | Jul 2, 2012 |
| Countries | Austria, Belgium, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Portugal, Spain and 2 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: